glp-1 patient education pdf Nutritional priorities to support therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society GLP-1 receptor agonists for individualized

Read the full article in Journal of Substance Abuse Treatment: Learn more about the implementation research in addiction: #ImplementationScience #AddictionResearch #EvidenceBased #NIH #NIDA #PublicHealth #ResearchToPractice To view or add a comment, sign in GLP-1 drugs, originally developed for diabetes and obesity, may also curb addictive behaviors by acting on reward circuits in the brain

,

doi: 10.3389/fcimb.2021.729346 Received 23 June 2021 Accepted 25 August 2021 Published 23 September 2021 Volume 11 - 2021 Edited by Sarah C

Common side effects Most people experience mild to moderate side effects, especially when starting the medication or adjusting to a higher dose